Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
The Role of Baseline Biomarkers in Treatment Planning Before starting a GLP-1, your provider should evaluate fasting glucose, HbA1c, lipid panel, liver enzymes, kidney function, and inflammatory markers
Some interventions sit between the two camps A few options produce effects that outlast a nootropics washout but fall short of a permanent structural change
If insurance denies coverage or charges prohibitive copays, compounded semaglutide at $199 monthly makes long-term treatment financially feasible
Miquana Renteria filed a complaint (PDF) in the U.S
Your Medicare copay is higher than the drugs SingleCare price
Xtandi (enzalutamide) Disease area(s): Oncology Manufacturer(s): Astellas/Pfizer 2024 Sales (USD): $7.94 billion Why it sold so well: In 2024, Astellas Pharmas Xtandi, co-marketed with Pfizer, posted strong sales growth, with revenues reaching 703.1 billion ($4.64 billion) for the first nine months (April 1, 2024 to December 31, 2024), marking a 25.6% increase compared to the same period in the previous year
US$ 25.16
US$ 21.93
US$ 27.82
US$ 24.49
US$ 28.02
US$ 27.79
US$ 20.81
